## Juliana Alvares

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2495237/publications.pdf

Version: 2024-02-01

393982 500791 1,292 105 19 28 citations g-index h-index papers 115 115 115 1676 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Economic evaluation of adalimumab versus etanercept for psoriatic arthritis in a Brazilian real-world model. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 473-479.	0.7	4
2	Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 119-129.	0.7	12
3	Social and economic factors associated with antidepressant use: Results of a national survey in primary care. Journal of Affective Disorders Reports, 2022, 8, 100307.	0.9	2
4	Functionality assessment in patients with rheumatic diseases undergoing treatment in the Public Health System. Einstein (Sao Paulo, Brazil), 2022, 20, eAO6453.	0.3	0
5	Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs for Psoriatic Arthritis: Findings and Implications From a Patient Centered Longitudinal Study in Brazil. Frontiers in Pharmacology, 2022, 13, 878972.	1.6	2
6	Biological therapy in psoriatic arthritis patients with and without previous biologic experience. Medicina, 2022, 55, .	0.0	0
7	Strategies to improve the availability of medicines in primary health care in Brazil: findings and implications. Journal of Comparative Effectiveness Research, 2021, 10, 243-253.	0.6	4
8	Saúde mental em estudantes universitários durante a pandemia de COVID-19. Revista FamÃlia, Ciclos De Vida E Saúde No Contexto Social, 2021, 9, 372.	0.1	7
9	A cross-sectional study of the quality of life of patients living with type 1 diabetes treated with insulin glargine and neutral protamine Hagedorn insulin and the implications. Journal of Pharmaceutical Health Services Research, 2021, 12, 332-342.	0.3	3
10	Dezesseis Anos de Transplante CardÃaco em Coorte Aberta no Brasil: Análise de Sobrevivência de Pacientes em Uso de Imunossupressores. Arquivos Brasileiros De Cardiologia, 2021, 116, 744-753.	0.3	2
11	Influence of pharmaceutical services organization on the availability of essential medicines in a public health system. Journal of Comparative Effectiveness Research, 2021, 10, 519-532.	0.6	4
12	Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study. Journal of Comparative Effectiveness Research, 2021, 10, 509-517.	0.6	3
13	Twelve months of emicizumab prophylaxis in a severe hemophilia A man with inhibitor who failed immune tolerance induction: effectiveness, economic, and safety outcomes. Hematology, Transfusion and Cell Therapy, 2021, , .	0.1	1
14	Budget impact analysis of medicines: estimated values versus real-world evidence and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, , 1-11.	0.7	3
15	Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study. Pharmacy Practice, 2021, 19, 2312.	0.8	5
16	Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Oncology and Therapy, 2021, 9, 505-524.	1.0	6
17	Access to medicines in the Brazilian Unified Health System's primary health care: assessment of a public policy. Journal of Comparative Effectiveness Research, 2021, 10, 869-879.	0.6	3
18	Cost-minimization analysis of teledermatology versus conventional care in the Brazilian National Health System. Journal of Comparative Effectiveness Research, 2021, 10, 1159-1168.	0.6	2

#	Article	IF	CITATIONS
19	Health-Related Quality of Life in Psoriatic Arthritis: Findings and Implications. Value in Health Regional Issues, 2021, 26, 135-141.	0.5	8
20	A longitudinal model for psychological distress in the COVID-19 crisis among brazilian graduate students. Psico, 2021, 52, e41332.	0.1	1
21	Impactos do avanço da pandemia de COVID-19 na saúde mental de profissionais de saúde. Psico, 2021, 52, e41302.	0.1	O
22	Survival Analysis of COPD Patients in a 13-Year Nationwide Cohort Study of the Brazilian National Health System. Frontiers in Big Data, 2021, 4, 788268.	1.8	0
23	Validity of the Frequency of Suicidal Ideation Inventory in Brazilian adults. Death Studies, 2020, , 1-5.	1.8	2
24	Integrative Review of Managed Entry Agreements: Chances and Limitations. Pharmacoeconomics, 2020, 38, 1165-1185.	1.7	25
25	Polypharmacy among adult and older adult users of primary care services delivered through the Unified Health System in Minas Gerais, Brazil. Expert Review of Clinical Pharmacology, 2020, 13, 1401-1409.	1.3	1
26	Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 21, 1-6.	0.7	4
27	Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study. PLoS ONE, 2020, 15, e0238476.	1.1	4
28	FIRST LINE OF SUBCUTANEOUS ANTI-TNF THERAPY FOR RHEUMATOID ARTHRITIS: A PROSPECTIVE COHORT STUDY. Expert Review of Clinical Immunology, 2020, 16, 1217-1225.	1.3	2
29	Realâ€world evaluation of the impact of statin intensity on adherence and persistence to therapy: A Scottish populationâ€based study. British Journal of Clinical Pharmacology, 2020, 86, 2349-2361.	1.1	16
30	Uso de medicamentos por adultos na atenção primária: inquérito em serviços de saúde de Minas Gerais, Brasil. Revista Brasileira De Epidemiologia, 2020, 23, e200025.	0.3	6
31	Academic detailing program for rheumatoid arthritis: a contribution to Brazilian public health system sustainability. Journal of Pharmaceutical Health Services Research, 2020, 11, 249-254.	0.3	3
32	PP406 Academic Detailing For Judges: Concepts Of Evidence-Based Medicine And Health Policies Adopted In Brazil. International Journal of Technology Assessment in Health Care, 2020, 36, 34-35.	0.2	0
33	Sixteen-Year Cohort of Liver Transplantation in the National Health System in Brazil: Analysis of Immunosuppression Maintenance Therapies. Frontiers in Pharmacology, 2020, 11, 572043.	1.6	1
34	Who should pay for the continuity of post-trial health care treatments?. International Journal for Equity in Health, 2019, 18, 26.	1.5	10
35	Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations. Expert Review of Clinical Immunology, 2019, 15, 879-887.	1.3	14
36	Confidentiality agreements: a challenge in market regulation. International Journal for Equity in Health, 2019, 18, 11.	1.5	8

#	Article	IF	Citations
37	Medication persistence for psoriatic arthritis in a Brazilian real-world setting. Future Science OA, 2019, 5, FSO369.	0.9	13
38	First line of biological drugs in rheumatoid arthritis: a medication persistence analysis. Expert Review of Clinical Pharmacology, 2019, 12, 363-370.	1.3	9
39	Access to high-cost medications for psoriatic arthritis in the National Health System in Brazil: the long path up to dispensation. Advances in Rheumatology, 2019, 59, 48.	0.8	11
40	Indicator of access to medicines in relation to the multiple dimensions of access. Journal of Comparative Effectiveness Research, 2019, 8, 1027-1041.	0.6	12
41	REGIME TERAPÊUTICO E QUALIDADE DE VIDA DE PACIENTES HIPERTENSOS. Revista De Atenção à Saúde, 2019, 16, .	0.0	0
42	Quality of Life of Patients with Type 1 Diabetes Mellitus Using Insulin Analog Glargine Compared with NPH Insulin: A Systematic Review and Policy Implications. Patient, 2018, 11, 377-389.	1.1	37
43	Statin use in Brazil: findings and implications. Current Medical Research and Opinion, 2018, 34, 1809-1817.	0.9	21
44	The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil. Pharmacoeconomics, 2018, 36, 161-173.	1.7	17
45	PP44 Effectiveness Of Insulin Glargine Versus Detemir In Type 1 Diabetes. International Journal of Technology Assessment in Health Care, 2018, 34, 82-83.	0.2	0
46	PP114 Clinical Effectiveness Of Insulin Glargine; Findings And Implications. International Journal of Technology Assessment in Health Care, 2018, 34, 109-109.	0.2	0
47	PP118 Cardiac Safety Of Trastuzumab For Metastatatic Breast Cancer. International Journal of Technology Assessment in Health Care, 2018, 34, 111-111.	0.2	0
48	PP76 Providing Information About Rheumatoid Arthritis Guideline In Brazil. International Journal of Technology Assessment in Health Care, 2018, 34, 96-97.	0.2	0
49	Crohn's Disease Treatment Expenditures over Fifteen Years of Follow-Up. Pharmacoeconomics Open Access, 2018, 03, .	0.1	0
50	PP142 Is Insulin Therapy Important For The Quality Of Life Of Diabetics?. International Journal of Technology Assessment in Health Care, 2018, 34, 122-122.	0.2	0
51	Effectiveness and safety of anti-TNF in psoriatic arthritis patients in Brazil: a post-incorporation analysis. Journal of Comparative Effectiveness Research, 2018, 7, 989-1000.	0.6	10
52	Effectiveness and safety of insulin glargine <i>versus</i> detemir analysis in patients with type 1 diabetes: systematic review and meta-analysis. Therapeutic Advances in Endocrinology and Metabolism, 2018, 9, 241-254.	1.4	12
53	The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil. PLoS ONE, 2018, 13, e0199446.	1.1	19
54	Profile of patients with head and neck cancer and evaluation of the quality of medical records in a public hospital. Revista Médica De Minas Gerais, 2018, 28, .	0.0	0

#	Article	IF	CITATIONS
55	The clinical effectiveness of insulin glargine in patients with Type I diabetes in Brazil: findings and implications. Journal of Comparative Effectiveness Research, 2017, 6, 519-527.	0.6	12
56	Access To Medicines: Developing An Indicator To Assess The Impact of Public Policies. Value in Health, 2017, 20, A898.	0.1	0
57	HEALTH TECHNOLOGY PERFORMANCE ASSESSMENT: REAL-WORLD EVIDENCE FOR PUBLIC HEALTHCARE SUSTAINABILITY. International Journal of Technology Assessment in Health Care, 2017, 33, 279-287.	0.2	32
58	Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia $\hat{A}^{\text{@}}$ ) in Brazil; Implications for Future Pricing Considerations. Frontiers in Pharmacology, 2017, 8, 41.	1.6	31
59	Pharmaceutical services in primary health care: interfederative agreement in the development of pharmaceutical policies in the Brazilian Unified Health System (SUS). Revista De Saude Publica, 2017, 51, 2s.	0.7	10
60	Health-related quality of life of patients of Brazilian primary health care. Revista De Saude Publica, 2017, 51, 22s.	0.7	20
61	Characterization of the selection of medicines for the Brazilian primary health care. Revista De Saude Publica, 2017, 51, 9s.	0.7	6
62	Infrastructure of pharmacies of the primary health care in the Brazilian Unified Health System:. Revista De Saude Publica, 2017, 51, 13s.	0.7	23
63	Access to medicines:. Revista De Saude Publica, 2017, 51, 8s.	0.7	13
64	Patient satisfaction with pharmaceutical services in Brazilian primary health care. Revista De Saude Publica, 2017, 51, 21s.	0.7	19
65	Management of pharmaceutical services in the Brazilian primary health care. Revista De Saude Publica, 2017, 51, 15s.	0.7	20
66	Use of medicines by patients of the primary health care of the Brazilian Unified Health System. Revista De Saude Publica, 2017, 51, 18s.	0.7	18
67	Financing of Pharmaceutical Services in the municipal management of the Brazilian Unified Health System. Revista De Saude Publica, 2017, 51, 14s.	0.7	11
68	Access to medicines by patients of the primary health care in the Brazilian Unified Health System. Revista De Saude Publica, 2017, 51, 20s.	0.7	25
69	Characterization of the institutionalization of pharmaceutical services in Brazilian primary health care. Revista De Saude Publica, 2017, 51, 7s.	0.7	6
70	Pharmaceutical services in the primary health care of the Brazilian Unified Health System:. Revista De Saude Publica, 2017, 51, 3s.	0.7	14
71	Medicine dispensing service in primary health care of SUS. Revista De Saude Publica, 2017, 51, 11s.	0.7	23
72	Main characteristics of patients of primary health care services in Brazil. Revista De Saude Publica, 2017, 51, 17s.	0.7	44

#	Article	lF	CITATIONS
73	Pharmaceutical care in Brazil's primary health care. Revista De Saude Publica, 2017, 51, 6s.	0.7	33
74	VP49 Brazilian Consumer Willingness To Pay For Dengue Vaccine (CYD-TDV). International Journal of Technology Assessment in Health Care, 2017, 33, 170-171.	0.2	0
75	VP53 Cost-Utility Analysis: Adalimumab Verus Etanercept in Rheumatoid Arthritis – Brazil. International Journal of Technology Assessment in Health Care, 2017, 33, 171-172.	0.2	0
76	Polypharmacy:. Revista De Saude Publica, 2017, 51, 19s.	0.7	43
77	National Survey on Access, Use and Promotion of Rational Use of Medicines: methods. Revista De Saude Publica, 2017, 51, 4s.	0.7	37
78	Technical issues and conservation conditions of medicines in the primary health care of the Brazilian Unified Health System. Revista De Saude Publica, 2017, 51, 12s.	0.7	20
79	Availability of essential medicines in primary health care of the Brazilian Unified Health System. Revista De Saude Publica, 2017, 51, 10s.	0.7	44
80	Indicators related to the rational use of medicines and its associated factors. Revista De Saude Publica, 2017, 51, 23s.	0.7	30
81	OP129 Predictors Of Effectiveness In Patients With Rheumatoid Arthritis. International Journal of Technology Assessment in Health Care, 2017, 33, 59-60.	0.2	0
82	Conceptions on pharmaceutical services in Brazilian primary health care. Revista De Saude Publica, 2017, 51, 5s.	0.7	12
83	Workforce in the pharmaceutical services of the primary health care of SUS, Brazil. Revista De Saude Publica, 2017, 51, 16s.	0.7	14
84	Implementation of clinical guidelines in Brazil: should academic detailing be used?. Journal of Pharmaceutical Health Services Research, 2016, 7, 105-115.	0.3	14
85	Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil. Expert Review of Clinical Pharmacology, 2016, 9, 991-999.	1.3	15
86	Clinical Effectiveness and Safety of Analog Glargine in Type 1 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Therapy, 2016, 7, 241-258.	1.2	21
87	Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System. Journal of Comparative Effectiveness Research, 2016, 5, 539-549.	0.6	13
88	Quality of life of patients with Diabetes Mellitus Types 1 and 2 from a referal health centre in Minas Gerais, Brazil. Expert Review of Clinical Pharmacology, 2016, 9, 739-746.	1.3	30
89	Budget impact analysis of medicines: updated systematic review and implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 257-266.	0.7	31
90	Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG. Brazilian Journal of Pharmaceutical Sciences, 2015, 51, 709-719.	1.2	4

#	Article	IF	CITATIONS
91	Poorer functionality is related to better quality of life response following the use of biological drugs: 6-month outcomes in a prospective cohort from the Public Health System ( <i>Sistema Único de) Tj ETQq1</i>	10.7843	14 <sub>11</sub> rgBT /0
	15, 403-412.		
92	There Is Evidence of Increased Risk of Cancer In Patients Using Human Insulin Analogue Glargine For Treatment of Diabetes Mellitus - Overview Based Evaluation. Value in Health, 2015, 18, A863.	0.1	0
93	Efficacy And Safety of Antidiabetic Drugs Available on Brazilian Public Health System (Sus) – Regular Insulin, Nph Insulin, Metformin, Glibenclamide And Gliclazide – In Treatment of Type 2 Diabetes (T2dm) - Systematic Review And Meta-Analysis. Value in Health, 2015, 18, A862.	0.1	1
94	Análise De Impacto Orçamentário: Quanto Custaria Ao Sistema Público De Saúde Brasileiro Incrementar, Por Meio De Transplantes, O Tratamento Da Doença Renal Crônica Terminal?. Value in Health, 2013, 16, A665.	0.1	1
95	Quality of life of patients in renal replacement therapy in Brazil: comparison of treatment modalities. Quality of Life Research, 2012, 21, 983-991.	1.5	48
96	Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil. Aids, 2005, 19, S5-S13.	1.0	81
97	Media Doctor Brasil: avaliação da qualidade de notÃcias em saúde. , 0, , .		O
98	Zolgensma e Atrofia Muscular Espinhal: evidências, incertezas e impacto orçamentário. , 0, , .		0
99	ANÃLISE DE EFETIVIDADE E SEGURANÇA DOS AGENTES ANTI - FATOR DE NECROSE TUMORAL PARA O TRATAMENTO DA ESPONDILITE ANQUILOSANTE NO SISTEMA ÊNICO DE SAÊDE: o SUS é para todos?. , 0, , .		O
100	PERSISTÊNCIA NO TRATAMENTO COM MEDICAMENTOS BIOLÓGICOS PARA ARTRITE PSORÃACA., 0, , .		0
101	Burosumabe para tratamento de pacientes com raquitismo hipofosfat $ ilde{A}^{\varphi}$ mico. , 0, , .		O
102	Voretigene neparvovec: a nova terapia gênica para doenças oculares. , 0, , .		0
103	MEIAS COMPRESSIVAS NA PREVENÃ $\sharp$ Ã $f$ O DE Ã $\sharp$ LCERAS VENOSAS. , 0, , .		O
104	PCDT da HPN: experiência na elaboração de um protocolo rápido. , 0, , .		0
105	A Cross-Sectional Study of Quality of Life Among Brazilian Adults With Type 1 Diabetes Treated With Insulin Glargine: Findings and Implications. Clinical Diabetes, 0, , .	1.2	O